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Background: Obstructive sleep apnea (OSA) is becoming increasingly prevalent in North America and has been
described in association with specific chronic diseases, particularly cardiovascular diseases. In primary care, where
the prevalence of co-occurring chronic conditions is very high, the potential association with OSA is unknown. The
purpose of this study was to explore the association between OSA and 1) the presence and severity of
multimorbidity (multiple co-occurring chronic conditions), and 2) subcategories of multimorbidity.
Methods: A cluster sampling technique was used to recruit 120 patients presenting with OSA of various severities
from the records of a sleep laboratory in 2008. Severity of OSA was based on the results of the polysomnography.
Patients invited to participate received a mail questionnaire including questions on sociodemographic
characteristics and the Disease Burden Morbidity Assessment (DBMA). They also consented to give access to their
medical records. The DBMA was used to provide an overall multimorbidity score and sub-score of diseases affecting
various systems.
Results: Bivariate analysis did not demonstrate an association between OSA and multimorbidity (r = 0.117;
p= 0.205). However, severe OSA was associated with multimorbidity (adjusted odds ratio = 7.33 [1.67-32.23],
p= 0.05). OSA was moderately correlated with vascular (r = 0.26, p= 0.01) and metabolic syndrome (r = 0.26, p= 0.01)
multimorbidity sub-scores.
Conclusions: This study showed that severe OSA is associated with severe multimorbidity and sub-scores of
multimorbidity. These results do not allow any causal inference. More research is required to confirm these
associations. However, primary care providers should be aware of these potential associations and investigate OSA
when deemed appropriate.
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Millions of North Americans are affected by the conse-
quences of sleep disorders. Among these disorders, sleep
apnea syndrome has the highest rate of mortality and
morbidity [1]. According to the Public Health Agency of
Canada, 858,900 Canadians reported suffering from
sleep apnea, and almost 26% of Canadians are at high
risk of developing the condition [2]. This disorder poses
a major public health problem due to its prevalence, se-
verity and socioeconomic burden. Obstructive sleep
apnea (OSA) is defined as the cessation of naso-buccal
air flow for more than 10 seconds [3], and is diagnosed* Correspondence: Martin.Fortin@USherbrooke.ca
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distribution, and reproduction in any mediumbased on an apnea–hypopnea index (AHI) value greater
than five per hour of sleep [4], usually accompanied by a
4% decrease in oxygen saturation [4]. It is estimated that
80% of obstructive sleep apnea cases remain undiag-
nosed [5], making it difficult to identify patients at risk
of associated comorbidities [6]. Reuveni et al. suggest
that programs be developed to increase the level of sus-
picion of OSA among primary care providers [7].
OSA syndrome is independently associated with an
increased risk of mortality [8,9]. Fletcher [10] reported
that 70% to 90% of patients with OSA have hypertension
[10]. Associations between OSA and heart failure [11],
OSA and arrhythmias [12], OSA and diabetes [13], OSA
and insulin resistance [14] and OSA and metabolic syn-
drome [15] have also been reported. Successful treat-
ment of OSA helps to better control many of the
associated diseases and chronic conditions [11,16-18].
Men, people 40 years old and over, and those with a highd Central Ltd. This is an Open Access article distributed under the terms of the
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are at greater risk for OSA [19-21].
Multimorbidity—the co-occurrence of two or more
chronic diseases—is an emerging concept in the medical
literature [22]. One study showed that nine out of ten
primary care patients had more than one chronic condi-
tion, while approximately 50% had five or more [23].
Multimorbidity has been associated with several adverse
effects, such as a reduction in quality of life [24,25], an
increase in psychological distress [26], medical complica-
tions and increased mortality [27].
Evidence of an association between OSA and multi-
morbidity could be an important incentive for the
systematic screening for OSA in primary care settings—
where the prevalence of multimorbidity is very high. The
first objective of this study was to measure the associ-
ation between the severity of OSA and the severity of
multimorbidity, and second, to explore the association
between OSA and various categories of multimorbidity.
Methods
This study used data from the sleep laboratory of the
Centre de santé et de services sociaux de Chicoutimi
(CSSSC), a regional health centre in the Saguenay region
of Québec (Canada). As a first step in the recruitment
process, a list of patients who had undergone polysom-
nography in 2008 was compiled. Patients were categor-
ized according to the severity of their OSA, based on
their polysomnography results (absent: AHI 0-4; mild:
AHI 5-14; moderate: AHI 15-29; severe: AHI ≥ 30). We
selected consecutive patients from each category to en-
sure a proportional representation (25% each) of the four
OSA categories. French-speaking patients were selected
between 30 and 75 years of age, to ensure adequate vari-
ation in degrees of multimorbidity. Each patient under-
went polysomnography after January 1, 2008, either
in the sleep laboratory as a full night or a split-night
study: the first half of the night is used to obtain a diag-
nosis, the second half is used to perform continuous
positive airway pressure (CPAP) titration (level I), or, at
home as an outpatient (level II). Patients with a diagno-
sis of upper airway resistance were excluded from the
study, as were people who slept less than three hours a
night and those referred for a diagnosis other than
apnea, such as parasomnia.
After providing informed consent, participants
selected at this stage received a questionnaire covering
multimorbidity and socio-demographic variables. Data
related to variables of the evaluation conducted at the
sleep laboratory were recorded: age, sex, polysomnogra-
phy results, neck circumference, weight and height.
Several tools are available for measuring multimorbid-
ity. The Disease Burden Morbidity Assessment (DBMA)
was selected for this study as it allows to report theabsence or presence of 21 predetermined chronic condi-
tions and additional chronic conditions and to deter-
mine a functional impact score for each condition on
daily life activities [28]. The DBMA is a self-report ques-
tionnaire. For each condition present, the patient
assesses a degree to which the condition limits his or
her activities on a five-point descriptive scale (1: Not at
all – 5: A lot). The total score is made up of the sum of
all limitations. The metrological qualities and validity of
this instrument have been described by Bayliss et al. [28]
and a French version was validated in a recent study:
sensitivity 73.9% (62.5%-90%); specificity 92.2% (77.6%-
98.6%) [29]. The questionnaire was sent by mail based
on a modified Dillman method [30]. A second question-
naire was sent to non-respondents 30 days following the
first one. Estimated time to complete the questionnaire
is approximately 15 minutes.
Due to the exploratory nature of the study, we based
our sample size estimation on the availability of the data
and feasibility. We aimed for a sample size of 120 (30
per OSA group) to ensure a good representation of each
category of the independent variable. We oversampled
for a potential non response of 30 to 40%. Consequently,
the questionnaire was sent to a convenience sample, as
recommended by Dillman [31], of 194 people who had
undergone polysomnography at the sleep laboratory of
the CSSSC for a diagnosis of sleep apnea in 2008. The
study received ethics approval from the Research Ethics
Board of the CSSSC.
The subject’s characteristics were described using med-
ians (in the case of asymmetric distributions), means,
standard deviations (for continuous variables) and pro-
portions (for categorical variables). A Kolmogorov-
Smirnoff test was performed to test for normality of the
distributions. In the absence of normality, non-parametric
tests were conducted. Bivariate (Spearman rank) correla-
tions were conducted. We dichotomized the AHI by
grouping together absent and mild as well as moderate
and severe to ensure sufficient size of each group. We
performed logistic regression analyses to study the rela-
tionship between multimorbidity and OSA. The signifi-
cance level was set at 0.05, and confidence intervals were
calculated at 95%. The DBMA constituted the dependent
variable and OSA classification, the independent variable.
Other variables were included in the models as adjust-
ment variables (BMI, sociodemographic variables). Neck
circumference was not included, as 25% of the data was
missing. We dichotomized the DBMA using the median
and threshold values of 10 and 20, respectively, to explore
the association with clinical variables. Cut-off points were
chosen based on the definition of multimorbidity and the
results of previous studies [23,32]. A score of 10 means a
high impact and at least two chronic conditions; a score
of 20 represents a very high impact and at least four
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bidity). DBMA sub-groups were formed on the basis of
the correlation of each disease with OSA and the concep-
tual association. We tested three sub-groups: vascular
DBMA (hypertension, heart disease, dyslipidemia, heart
failure and stroke); cardio DBMA (hypertension, heart
disease, dyslipidemia, heart failure) and metabolic syn-
drome DBMA (hypertension, cholesterol, obesity and dia-
betes). Data were analyzed using the SPSS package (19.0,
SPSS, Chicago. IL).
Results
Of the 194 patients solicited, seven were non-eligible:
five were suffering from parasomnia, one was too old
and one we were unable to reach to complete the ques-
tionnaire. In total, 187 eligible patients were invited to
participate and 120 completed the questionnaire (64.2%
response rate). No patients were excluded. Among these,
89.2% of participants had OSA. The average age of
patients was 55.5 years, with a predominance of males
(65%).
Table 1 presents the characteristics of the 120 patients.
The average neck circumference (absent: 41.17 cm; mild:
40.5 cm; moderate: 42.59 cm; severe: 43.99 cm) and BMI
average (absent: 32.00; mild: 30.13; moderate: 34.39; se-
vere: 35.77) were higher in moderate and severe OSA.
The 120 respondents presented six chronic diseases in
average. The average number of diseases did not in-
crease in accordance with the severity of OSA (absent:
seven diseases; mild: five diseases; moderate: eight dis-
eases; severe: five diseases). Table 2 (DMBA results)
shows the distribution of diseases in the sample. The
following conditions were present in 50% or more of the
patients: obesity (80.8%), hypertension (52.5%) and dysli-
pidemia (50%).
Table 3 reveals an association between polysomnogra-
phy results (absent + mild vs. moderate + severe) and
BMI (r = 0.261, p= 0.01) and gender (r = 0.244, p= 0.01)




Polysomnography results (%) 13 (10.8) 23
Neck circumference * 41.17 ± 4.98 40.4
Mean ± standard deviation (min and max) (34.7-50.5) (31.
Body mass index 32.0 ± 6.7 30.
Mean ± standard deviation (min and max) (22-47) (1
DBMA 16.0 ± 11.1 14.
Mean ± standard deviation (min and max) (2-36) (0
Mean number of diseases 7 diseases 5 d
* N = 90.p= 0.05), and with income (r = 0.218, p= 0.05). We were
unable to demonstrate a statistically significant associ-
ation between the DBMA score and dichotomized poly-
somnography (absent + mild vs. moderate + severe)
(r = 0.117, p=NS) in this analysis. With regard to multi-
morbidity sub-scores, Table 3 shows weak correlations
between sleep apnea and vascular DBMA and between
OSA and metabolic syndrome DBMA. None of the
sociodemographic variables were associated with OSA.
Tables 4 and 5 show a significant association between
severity of DBMA and severe OSA. There was also a sig-
nificant association between DBMA and severe OSA (an
AHI over 30). This association was not observed in
patients with mild to moderate OSA. None of the sub-
scores presented in Table 3 showed an association with
severity of OSA in logistic regression analyses (results
not shown).
Discussion
The present study revealed an association between se-
vere OSA and severity of multimorbidity as measured by
the DBMA. The relationship was still present after
adjusting for several potential confounders.
These findings have implications for general practice.
Many patients seen in primary care practices present
with multimorbidity. In order to investigate the potential
association between multimorbidity and OSA, screening
could be done clinically or by using a tool such as the
Epworth Instrument which is highly correlated with
OSA [33]. Patients could be referred to a sleep lab for
evaluation when OSA is suspected. If OSA is confirmed,
it may affect the management of the patient who could
benefit from treatment that has been demonstrated to
help control many associated diseases and chronic con-
ditions [11,16-18].
One previous study suggests that multimorbidity exists
in OSA [34]. To our knowledge, this is the first study to
report an association between severe OSA and multi-
morbidity. We searched for an exposure–responseAHI Total
ild Moderate Severe
-14) (15-29) (30 and over)
(19.2) 36 (30.0) 48 (40.0)
9 ± 4.12 42.59 ± 5.23 43.99 ± 3.61 42.28 ± 5. 63
0-47.0) (32.0-59.9) (37.0-51.5) (31.0-59.9)
1 ± 6.7 34.4 ± 7.2 35.8 ± 7.7 33.9 ± 7.4
8-42) (24-60) (21-65) (18-65)
5 ± 9.6 21.2 ± 11.4 15.3 ±11.8 16.9 ± 11.5
-40) (2-40) (1-55) (0-55)
iseases 8 diseases 5 diseases 6 diseases
Table 2 DBMA results
Disease AHI Sampling
percentage0 - 4 5 - 14 16 - 29 (≥ 30)
Obesity 10 (8.3%) 17 (14.2%) 31 (25.9%) 39 (32.5%) 97 (80.8%)
Hypertension 6 (5%) 9 (7.5%) 21 (17.5%) 27 (22.5%) 63 (52.5%)
Dyslipidemia 4 (3.3%) 6 (5%) 24 (20%) 26 (21.7%) 60 (50.0%)
Ostheoarthritis 6 (5%) 11 (9.2%) 19 (15.8%) 15 (12.5%) 51 (42.5%)
Back pain or sciatica 6 (5%) 5 (4.2%) 20 (16.7%) 20 (16.7%) 51 (42.5%)
Gastrointestinal ulcer 5 (4.2%) 11 (9.2%) 19 (15.8%) 12 (10%) 47 (39.2%)
Leg circulation problems 4 (3.3%) 7 (5.8%) 18 (15%) 15 (12.5%) 44 (36.7%)
Other joint diseases 5 (4.2%) 6 (5%) 15 (12.5%) 15 (12.5%) 41 (34.2%)
Hearing disorder 1 (0.83%) 8 (6.7%) 11 (9.2%) 18 (15%) 38 (31.7%)
Depression and anxiety 7 (5.8%) 7 (5.8%) 9 (7.5%) 12 (10%) 35 (29.2%)
Diabetes 5 (4.2%) 3 (2.5%) 11 (9.2%) 12 (10%) 31 (25.8%)
Heart disease 2 (1.7%) 5 (4.2%) 9 (7.5%) 14 (11.7%) 30 (25.0%)
Asthma 3 (2.5%) 5 (4.2%) 13 (10.8%) 9 (7.5%) 30 (25.0%)
Vision disorder 1 (0.83%) 2 (1.7%) 9 (7.5%) 7 (5.8%) 19 (15.8%)
Osteoporosis 2 (1.7%) 3 (2.5%) 10 (8.3%) 3 (2.5%) 18 (15%)
Bowel disease 1 (0.8%) 4 (3.3%) 6 (5%) 5 (4.2%) 16 (13.3%)
Chronic bronchitis or emphysema 2 (1.7%) 2 (1.7%) 6 (5%) 5 (4.2%) 15 (12.5%)
Thyroid 1 (0.83%) 2 (1.7%) 4 (3.3%) 5 (4.2%) 12 (10.0%)
Heart failure 2 (1.7%) 0 3 (2.5%) 6 (5%) 11 (9.2%)
Stroke 0 2 (1.7%) 3 (2.5%) 5 (4.2%) 10 (8.3%)
Rheumatoid arthritis 0 0 3(2.5%) 2 (1.7%) 5 (4.2%)
Cancer 0 1 (0.8%) 2 (1.7%) 1 (0.8%) 4 (3.3%)
Table 3 Bivariate analysis with dichotomized
polysomnography results
Variable r* p value
BMI 0.261 0.01
Neck circumference 0.265 0.05
Sex 0.244 0.01
Income 0.218 0.05
Vascular DBMA (sub-score) 0.261 0.01
Cardiac DBMA (sub-score) 0.196 0.05
Metabolic syndrome DBMA (sub-score) 0.261 0.01
DBMA score 0.117 0.205
Age 0.132 0.151
Marital status 0.109 0.090
Place of birth 0.085 0.355
Education -0.026 0.780
Dichotomized polysomnography: 0 = absent + mild; 1 =moderate + severe
DBMA sub-score: Cardiac DBMA: Hypertension, heart disease, dyslipidemia,
heart failure; Vascular DBMA: Hypertension, heart disease, dyslipidemia, heart
failure, stroke;
Metabolic syndrome DBMA: Hypertension, cholesterol, obesity and diabetes
*Spearman correlation.
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composition of our sample prevented us from observing
such a relationship. In our sample we did not obtain the
desired proportion representation (25% each) of the four
severity categories of the independent variable (OSA: ab-
sent, mild, moderate and severe). We sent the DBMA
questionnaire to 50 people in each OSA classification
category but we had a disproportionately high responseTable 4 Logistic regressions unadjusted
Variable/Result OR p value 95% CI
Median DBMA (14.00) Mild: 1.31 0.670 0.38-4.50
Moderate: 1.17 0.755 0.49-3.21
Severe: 2.70 0.029 1.11-6.60
DBMA 10 Mild: 1.23 0.755 0.33-4.61
Moderate: 0.85 0.761 0.31-2.38
Severe: 3.40 0.031 1.15-10.36
DBMA 20 Mild: 1.33 0. 675 0.35-5.13
Moderate: 0.63 0.475 0.18-2.23
Severe: 3.00 0.020 1.19-7.56
Median DBMA: 0 =DBMA from 0 to 13.99 and 1= 14 and over.
DBMA 10: 0 =DBMA from 0 to 9.99 and 1 = 10 and over.
DBMA 20: 0 =DBMA from 0 to 19.99 and 1 = 20 and over.
Table 5 Logistic regression analyses adjusted for sex,
age, BMI and income
Variable/result OR p value 95% CI
Median DBMA (14.00) Mild: 0.90 0.909 0.16-5.03
Moderate: 0.92 0.912 0.22-3.84
Severe: 3.94 0.021 1.24-12.59
DBMA 10 Mild: 1.41 0.696 0.25-7.92
Moderate: 0.83 0.798 0.26-3.37
Severe: 4.34 0.021 1.22-15.44
DBMA 20 Mild: 1.12 0.911 0.16-7.75
Moderate: 0.32 0.229 0.05-2.07
Severe: 7.33 0.008 1.67-32.23
Median DBMA: 0 =DBMA from 0 to 13.99 and 1= 14 and over.
DBMA 10: 0 =DBMA from 0 to 9.99 and 1 = 10 and over.
DBMA 20: 0 =DBMA from 0 to 19.99 and 1 = 20 and over.
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compared to the others. On the other hand, we obtained
a sample of relatively sicker subjects (an average DBMA
of 16). Patients in this study presented more chronic
conditions (six per person) than reported by Fortin [23]
(4.6 per person) or Kadam (1.3 per person) [32] in their
assessment of multimorbidity in primary care practices.
We suspect that the disproportionate response rate is
due to the fact that patients who were sicker were more
interested in participating in this study.
Regarding other characteristics and associations, the
respondents were fairly representative of the sleep apnea
population, with a predominance of male subjects [21].
Neck circumference and BMI were found to be posi-
tively associated with OSA, which was expected [21].
We observed an association between the AHI and meta-
bolic syndrome. This association had been previously
found by other groups [35,36]. Although not addressed
in our study, associations were also found between OSA
and each component of the metabolic syndrome. In fact,
the evidence suggests that OSA is actually part of the
metabolic syndrome. One study suggests that OSA
symptoms (snoring, hyper somnolence) predict the de-
velopment of metabolic syndrome. In addition, evalu-
ation of OSA symptoms can help identify individuals
who are at risk of developing metabolic syndrome [35].
Our sleep laboratory uses a definition of hypopnea
which is accepted in the literature: a decrease in respira-
tory amplitude of 50% or more, accompanied by a desat-
uration of 3% [37]. However, other laboratories require a
4% desaturation for a positive diagnosis. The method
used in this study is therefore more sensitive than the
diagnostic criteria used in some laboratories. This could
result in higher AHI values and the number of diagnoses
of patients with mild or moderate symptoms who would
not have been diagnosed by other laboratories. Several
epidemiological studies have established a relationshipbetween OSA and vascular morbidity using the 4% cut-
off point [38]. This may explain why we did not observe
any link between our groups of mild or moderate sub-
jects and a measure of morbidity. It is especially import-
ant that studies showing a link between sleep apnea and
morbidity examine these associations, particularly in the
case of severe OSA (AHI greater than 30). Also, if OSA
is an intermediate factor in the development of hyper-
tension, diabetes, dyslipidemia or other conditions, con-
trolling for these variables represents a case of "over
adjustment," potentially affecting the association be-
tween dependent and independent variables [39,40].
For more than 20 years, cross-sectional studies, con-
trol cases and other evidence have suggested an associ-
ation between OSA and heart disease, heart failure,
arrhythmias and cerebrovascular diseases [8,9,12,40]. A
gradation of vascular risk in relation to AHI has been
proposed [40]. We observed an association between vas-
cular DBMA and AHI when AHI was dichotomized into
absent and mild versus moderate and severe. Similar
results were obtained in prospective population studies,
such as the Sleep Heart Health Study [41] and the Wis-
consin Sleep Cohort Study [42]. In the first study, Got-
tlieb identified an association between incident heart
failure and OSA. Although there is no defined threshold
value, this association is especially important in subjects
with an AHI greater than 30. In the Wisconsin study,
the associations were significant only in subjects with an
AHI greater than 30 (odds ratios of 4.5 and 5.2, respect-
ively, for risks of cerebral vascular disease and cardiovas-
cular death). Furthermore, a longitudinal study showed
that men are at increased risk of stroke when the AHI is
greater than 19 per hour of sleep. Among women, un-
adjusted overall results showed an increased risk thresh-
old at 25 AHI per hour of sleep (p= 0.002) [39].
This study has limitations. With a limited response rate
of 64%, we were unable to obtain a proportional represen-
tation in categories of OSA classification in our sample,
and this may have confounded the relationship between
the DBMA and OSA. In addition, we had to remove one
variable from the analysis (neck circumference) due to a
high number of missing values. Another limitation of the
study is the use of the DBMA as a measure of multimor-
bidity. The DBMA measures self-reported disease burden
that correlates well with quality of life outcomes [28].
However, in other multimorbidity measures, disease se-
verity is evaluated based on purely clinical criteria
assessed by health professionals. The different methods of
evaluating disease severity may have an impact on the as-
sociation between multimorbidity and OSA.
Conclusions
In this study we found a link between severe obstructive
sleep apnea and severity of multimorbidity. These results
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tween severity of OSA and severity of multimorbidity.
The study also showed an association between OSA and
multimorbidity sub-scores (cardiac, vascular, metabolic
syndrome). Primary care providers should be aware of
these potential associations and investigate OSA when
deemed appropriate. There is a need for additional re-
search in this area, and our findings may help raise
awareness among family physicians about this condition
and improve access to diagnosis and treatment. Research
would benefit from repeating the same study using a
longitudinal study design.
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